Chorioretinitis

Summary

Chorioretinitis (MONDO:0004674) is a disease and 5 clinical trials. Top therapeutic interventions include clindamycin. A subtype of uveitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chorioretinitis
Mondo ID	MONDO:0004674
MeSH	D002825
DOID	DOID:8886
NCIT	C110923
SNOMED CT	46627006
UMLS	C0008513
MedGen	942
GARD	0006060
Is cancer (heuristic)	no

Also known as: chorioretinitis · chorioretinitis (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of uveitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › uveitis › chorioretinitis

Related subtypes (8): anterior uveitis, intermediate uveitis, iritis, posterior uveitis, suppurative uveitis, panuveitis, idiopathic posterior uveitis, autoimmune uveitis

Subtypes (4): microcephaly and chorioretinopathy, focal chorioretinitis, disseminated chorioretinitis, pars planitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Clindamycin	Phase 3 (in late-stage trials)
Pyrimethamine	Phase 3 (in late-stage trials)
Sulfadiazine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00372294	PHASE3	UNKNOWN	To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT03753893	Not specified	COMPLETED	Ocular Manifestations in Rheumatic Diseases
NCT04245072	Not specified	UNKNOWN	Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis
NCT05335746	Not specified	UNKNOWN	Ocular Changes in Vitiligo Patients on Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLINDAMYCIN	4	3